J 2023

Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment

VICHA, Marek, Tomas SKALA, Libor JELINEK, Ludek PAVLU, Jiří JARKOVSKÝ et. al.

Basic information

Original name

Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment

Authors

VICHA, Marek (203 Czech Republic), Tomas SKALA (203 Czech Republic, guarantor), Libor JELINEK (203 Czech Republic), Ludek PAVLU (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution) and Milos TABORSKY (203 Czech Republic)

Edition

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 0.900 in 2022

RIV identification code

RIV/00216224:14110/23:00129948

Organization unit

Faculty of Medicine

DOI

UT WoS

000731342200001

Keywords in English

diabetes mellitus; heart failure; pharmacotherapy; National Register of Paid Health Services (NRHZS)

Tags

Tags

International impact, Reviewed
Změněno: 26/1/2024 09:51, Mgr. Tereza Miškechová

Abstract

V originále

Aim. Retrospective national sub-analysis of antidiabetic pharmacotherapy in patients with diabetes mellitus (DM) and heart failure (HF) based on data reported to the National Register of Paid Health Services in the Czech Republic between 2012-2018. Methodology and Results. In 2012, there were 75,022 patients with HF and DM (i.e. 42.5% of patients with HF), 6 years later 117,265 (i.e. 41.0% of HF patients in 2018). The most represented antidiabetic drug was metformin (45.6%). Of the insulins and analogues, glargine showed the largest positive trend (5.8% 2012; 14.8% 2018). Empagliflozin was the most prescribed SGLT-2 inhibitor (1.8% in 2018). A decrease in prescribing was observed for saxagliptin (0.5% 2012; 0.1% 2018) and for sulfonylurea derivates - gliclazide (13.0% 2012; 10.3% in 2018) and glimepiride (12.9% 2012; 9.0% 2018). Linagliptin was the most prescribed dipeptidyl peptidase inhibitor (0.7% 2012; 6.8% 2018). Conclusion. In the Czech Republic, between 2012 and 2008, there was an increase in prevalence of patients with heart failure and concomitant diabetes mellitus, their proportion being similar. In correspondence with other registries, metformin was used mostly. A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas.